Skip to main content

Table 10 Comparison of the proposed and reported methods for determination of VAL

From: Quality by design approach for development and validation of a RP-HPLC method for simultaneous estimation of xipamide and valsartan in human plasma

Item

Proposed method

Reported method [17]

Reported method [18]

Reported method [19]

Technique

HPLC–UV

HPLC–UV

HPLC–UV

HPLC–UV

Matrix

Human plasma

Nano-formulation

Rabbit Plasma

Nano-formulation

Optimization strategy

Central Composite Design

Full factorial design

Full factorial design

One factor at a time

Mobile phase

Methanol: 0.05 M phosphate buffer, pH 3 (64.5:35.5, v/v)

Acetonitrile: 20 mM ammonium formate, pH 3 (43:57, v/v)

Acetonitrile: 20 mM ammonium formate (42:58 v/v)

Acetonitrile: 10 M phosphate buffer, pH 3.6 (60:40, v/v)

Analytes

XIP and VAL

VAL

VAL

VAL

LOD (ng/mL)

134

4.833

22.000

6.000

LOQ (ng/mL)

448

44.95

66.67

25

Retention time (min)

4.34

10.177

11.394

2.91

% Recovery ± SD

89.17 ± 7.38

 

94.81 ± 9.80

 

n

4

 

3

 

V

VAL: 54.47

 

96.13

 

t

0.835 (2.571)a

   

F

1.765 (9.53)b

   
  1. a,bTabulated t values and F ratios at p = 0.05